| 1. |
- Zelvyté, Inga, et al.
(författare)
-
Diverse responses between human pancreatic cancer cell lines to native alpha 1-antitrypsin and its C-terminal fragment.
- 2003
-
Ingår i: Anticancer research. - 1791-7530. ; 23:3B, s. 2267-2273
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Previous studies imply that human pancreatic cancer cells have a wide heterogeneity and their exposure to various agents may give unpredictable results in clinical situations. MATERIALS AND METHODS: The cell lines LPC-3, -5 and -10, established from primary cultures of pancreatic adenocarcinoma, were exposed to 5 microM of AAT or its C-terminal peptide C-36 for 24 hours and analysed for cytokines by an enzyme-linked immunosorbent assay and for NF kappa B by the electrophoretic mobility shift assay. RESULTS: Native AAT lowers TGF-beta 1 levels and increases NF-kappa B activity in LPC-3 cells, while C-36 increases TGF-beta 1 levels and up-regulates NF-kappa B in LPC-5 cells. In LPC-10 cells AAT lowers TGF-beta 1. However, both AAT and C-36 fail to cause a change in NF-kappa B expression. For LPC-10 cells treated with C-36 IL-6 and TNF-alpha levels also increase. CONCLUSION: Our findings provide evidence that human cancer cell lines originating from primary pancreatic tumors do not have a uniform response to the same stimulus which shows a great heterogenicity among pancreatic cancer cells. Serine proteinase inhibitor, AAT, dependent on its molecular form, is also found to exert diverse effects on the properties of tumour cells confirming the complexity of cell-protein interaction.
|
|
| 2. |
- Zelvyté, Inga, et al.
(författare)
-
Increased plasma levels of serine proteinase inhibitors in lung cancer patients.
- 2004
-
Ingår i: Anticancer research. - 1791-7530. ; 24:1, s. 7-241
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Tumor growth and invasiveness occur through infiltration of tumor cells into the host cells and by angiogenesis, which is modulated by proteinases and antiproteinases released from tumor cells that carry out tissue remodelling. A number of studies have revealed variations in the plasma levels of serine proteases and their inhibitors among tumor types. PATIENTS AND METHODS: By immunological methods we analysed the levels of serine protease inhibitors AAT, ACT and SLPI in newly diagnosed lung cancer patients (n=14) compared to non-smoker and smoker, age- and gender-matched control groups (n=16), and also in an expanded group of lung cancer patients with local tumors (n=14) and with metastasis (n=18). RESULTS: Our data show that plasma levels of AAT, ACT and SLPI were elevated in lung cancer patients by 1.43-fold, p<0.01, 2.57-fold, p<0.01 and 1.6-fold, p<0.001, respectively when compared to controls. In addition, we found that levels of AAT and ACT were higher by 1.47-fold, p<0.001 and 2.27-fold, p<0.001, respectively in lung cancer cases with metastasis compared to localized tumor. CONCLUSION: These inhibitor levels may provide measures of cancer progression in individual patients and possibly offer useful information for an understanding of the mechanisms of metastasis.
|
|
